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Abstract
Background: Alzheimer’s disease (AD) is the most common form of dementia. AD is a degenerative brain disorder that
causes problems with memory, thinking and behavior. It has been suggested that aggregation of amyloid-beta peptide (Ab)
is closely linked to the development of AD pathology. In the search for safe, effective modulators, we evaluated the
modulating capabilities of erythrosine B (ER), a Food and Drug Administration (FDA)-approved red food dye, on Ab
aggregation and Ab-associated impaired neuronal cell function.
Methodology/Principal Findings: In order to evaluate the modulating ability of ER on Ab aggregation, we employed
transmission electron microscopy (TEM), thioflavin T (ThT) fluorescence assay, and immunoassays using Ab-specific
antibodies. TEM images and ThT fluorescence of Ab samples indicate that protofibrils are predominantly generated and
persist for at least 3 days. The average length of the ER-induced protofibrils is inversely proportional to the concentration of
ER above the stoichiometric concentration of Ab monomers. Immunoassay results using Ab-specific antibodies suggest that
ER binds to the N-terminus of Ab and inhibits amyloid fibril formation. In order to evaluate Ab-associated toxicity we
determined the reducing activity of SH-SY5Y neuroblastoma cells treated with Ab aggregates formed in the absence or in
the presence of ER. As the concentration of ER increased above the stoichiometric concentration of Ab, cellular reducing
activity increased and Ab-associated reducing activity loss was negligible at 500 mM ER.
Conclusions/Significance: Our findings show that ER is a novel modulator of Ab aggregation and reduces Ab-associated
impaired cell function. Our findings also suggest that xanthene dye can be a new type of small molecule modulator of Ab
aggregation. With demonstrated safety profiles and blood-brain permeability, ER represents a particularly attractive
aggregation modulator for amyloidogenic proteins associated with neurodegenerative diseases.
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Introduction
Growing evidence suggests that protein misfolding and
aggregation closely correlate to the onset of numerous neurode-
generative diseases, such as Alzheimer’s disease (AD), Parkinson’s
disease (PD), and Huntington’s disease (HD). A common
pathological hallmark of these neurodegenerative diseases is the
accumulation of insoluble protein aggregates in the brain.
Amyloidogenic protein associated with AD, PD, and HD is
amyloid-beta peptide (Ab), a-synuclein, and huntingtin protein,
respectively. Although the exact cellular and molecular mecha-
nisms of protein aggregation remains unclear, there is increasing
evidence supporting the idea that aggregation of peptides/proteins
associated with the neurodegenerative diseases have common
cellular and molecular mechanisms [1,2]. Therefore, it was
hypothesized that protein aggregates associated with neurodegen-
erative disease have common structural features. Glabe et al.
discovered that an oligomer-specific antibody raised using
amyloid-beta peptide recognizes soluble oligomers of other types
of amyloids including a-synuclein, insulin, and polyglutamine [1],
demonstrating that soluble oligomers of amyloidogenic proteins
share common conformation. Numerous small molecules have
been tested for their ability to reduce toxic Ab aggregates
[3,4,5,6,7,8,9,10,11]. Recently Wanker et al. reported that (-)-
epigallocatechin gallate preferentially binds to unfolded mono-
meric a-synuclein and Ab and induces formation of non-toxic
oligomers, suggesting that small molecules modulate aggregation
of amyloidogenic proteins through a common molecular mecha-
nism [7]. However, the modulation of amyloidogenic protein
aggregation by the same small molecule via a common mechanism
has not been extensively explored. In order to validate this
concept, we chose one a-synuclein aggregation modulator,
erythrosine B (ER), considering its demonstrated safety profiles
evidenced by FDA approval as a food dye [12,13]. To our
knowledge, Ab modulating capacities of xanthenes dyes including
ER have not been reported. Herein, we evaluate the modulating
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e25752capacities of ER on Ab aggregation and Ab-induced impaired
cellular reducing activity in neuronal cells, and investigate whether
there are any common features in the interaction mode of
erythrosine B with between a-synuclein and Ab.
ER is a xanthene dye and is commonly used in coloring candies
and cakes (Figure 1). ER is listed in the US as FD&C Red No. 3, in
the EU as E127, and also in many other countries as a food
coloring dye. It exhibits no observable toxicity up to a daily dose of
149 mg/kg body mass in healthy animals [13]. Likewise, a daily
dose of 60 mg/kg does not exhibit any toxicity to humans [14].
ER is highly lipid soluble and so crosses the blood-brain barrier
(BBB) [15,16]. The in vivo BBB permeability value of ER is 39 ml/
min/g brain, though the condition of the subject can affect plasma
protein binding to ER leading to restricted brain uptake [16]. With
demonstrated safety profiles and BBB permeability, ER represents
a particularly attractive aggregation modulator for amyloidogenic
proteins associated with neurodegenerative diseases.
Materials and Methods
Ab Sample Preparation
Ab40 powder (Anaspec, Inc.) was added to 0.1% trifluoroacetic
acid (TFA) to obtain a 1.0 mM stock solution, which was then
incubated for one hour without agitation for complete dissolution
as described previously [17,18,19]. The freshly prepared 1.0 mM
stock Ab solution was diluted with phosphate buffered saline (PBS)
solution (10 mM NaH2PO4 and 150 mM NaCl at pH 7.4) to
obtain a 50 mMA b solution. 50 mMA b samples were then
incubated at 37uC for the specified time duration.
Transmission Electron Microscopy (TEM)
10 mLA b sample was spread onto a formvar mesh grid and
incubated for one min. The grids were then negatively stained with
2% uranyl acetate for 45 sec., dried and viewed on a Jeol JEM1230
Transmission Electron Microscope (80 kV)locatedat the Advanced
Microscopy Laboratory at the University of Virginia.
ThT Fluorescence Assay
5 mLo f5 0mMA b40 sample in the absence or in the presence
of ER was diluted in 250 mLo f1 0mM ThT in 96-well plates. ThT
fluorescence was measured using a Synergy 4 UV-Vis/fluores-
cence multi-mode microplate reader (Biotek, VT) at an emission
wavelength of 485 nm using an excitation wavelength of 450 nm.
Dot-blotting
2 mLo fA b samples were spotted onto a nitrocellulose membrane
and were dried at room temperature. The nitrocellulose membrane
was incubated in 5% skim milk dissolved in 0.1% Tween 20, Tris-
buffered saline (TBS-T) solution for one hour. The 5% milk TBS-T
solution was removed and the membrane waswashed threetimes (each
time for five minutes) with TBS-T solution. The membrane was then
incubated with antibody for one hour. Polyclonal A11 anti-oligomer
antibody and horseradish peroxidase (HRP)-conjugated anti-rabbit
antibody were obtained from Invitrogen (Carlsbad, CA). 4G8 antibody
was obtained from Abcam (Cambridge, MA). Monoclonal 6E10 and
polyclonal OC antibodies were obtained from Millipore (Billerica,
MA). The 4G8, OC, A11 and 6E10 antibodies were diluted in 0.5%
milk TBS-T solution according to the manufacturer’s protocols. After
incubation the membrane was washed three times for 5 minutes using
TBS-T solution. In the case of the HRP-conjugated antibody (4G8),
membranes were coated with 2 mL of detection agent from the ECL
Advance Detection Kit (GE Healthcare, NJ) and the fluorescence was
visualized. Otherwise, the membrane was incubated in (1:5000 dilution
in 0.5%milkTBS-T) HRP-conjugated secondary antibody solution for
one hour.Then the membrane waswashed three times (each time for 5
minutes) with TBS-T solution and the same detection method as
previously described was used. The blot images were taken using a
BioSpectrum imaging system (UVP, CA).
MTT Reduction Assay
Viability of Human neuroblastoma SH-SY5Y cells (American
Type Culture Collection) was determined by 3-(4,5-Dimethylthia-
zol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction.
50 mg of MTT (Millipore, MA) was dissolved overnight at 4uC
in 10 mL of PBS. The MTT solution was then sterile filtered. SH-
SY5Y cells were cultured in a humidified 5% CO2/air incubator
at 37uC in DMEM/F 12:1:1 modified media with 10% fetal
bovine serum and 1% penicillin-streptomycin (Thermo Scientific,
MA). 20,000 to 25,000 SH-SY5Y cells were seeded into each well
of 96-well plates and incubated for 48 hours. Then, the culture
medium was replaced with 100 mL of fresh media, and 10 mLo f
the Ab sample was added to each well to obtain a final Ab
concentration of 5 mM. Cells were incubated for an additional
48 hours. After replacing the culture medium with a fresh
medium, 10 mL of the sterile MTT solution was added, and cells
were incubated for 6 hours at 37uC in the dark. After dissolution
of the reduced MTT using 200 mL of DMSO, the absorbance was
measured at 506 nm using a Synergy 4 UV-Vis/fluorescence
multi-mode microplate reader.
Results and Discussion
Stabilization of Ab protofibrils and Inhibition of Ab fibril
formation by ER
In order to monitor morphological changes of Ab aggregates
and formation of amyloid fibrils, we employed TEM and ThT
fluorescence assays. TEM has been widely used to obtain
morphological information on Ab aggregates [20,21,22,23]. Ab
intermediates as well as fibrils can be directly visualized with
negative-stain TEM. ThT fluoresces at 485 nm when bound to
amyloid fibrils [9,24,25]. Therefore, ThT fluorescence is used to
monitor the progression of amyloid fibril formation. Ab samples
were prepared by incubating 50 mMo fA b monomer either in the
absence (control) or presence of ER from 0 to 3 days at 37uC
without shaking as described previously [17,18,19].
Figure 1. Chemical structure of erythrosine B (ER).
doi:10.1371/journal.pone.0025752.g001
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morphology among Ab samples incubated in the absence and in
the presence of ER (Figure 2). In the absence of ER, oligomers,
protofibrils, and amyloid fibril mesh network were sequentially
observed throughout the study (Figure 2, far-left panels). The onset
of fibril formation at day 2 was confirmed by a dramatic increase
in ThT fluorescence from 48 to 72 hr (Figure 3A). At day 1, in the
presence of 50 mM of ER (1x ER), protofibrils were the
predominant species (Figure 2, top 1x ER panel), whereas
oligomers were dominant in the absence of ER (Figure 2, top
far-left panel). Furthermore, these protofibrils were observed until
day 3 and appeared to have morphological homogeneity
characterized by similarity in length and width (Figure 2, 1x ER
panels). To evaluate this quantitatively, the length of two hundred
Ab aggregates including protofibrils and fibrils in TEM images at
each ER concentration were manually measured using ImageJ
(NIH). The length distribution of the two hundred Ab aggregates
at 1x, 5x, or 10x ER concentration is described in Table 1. At day
1, in the presence of 1x ER, the average protofibril length was 690
nm. In the presence of 1x ER, the average length protofibrils did
not change substantially on subsequent days (Table 1). At day 1,
increasing the ER concentration from 1x to 10x decreased the
average length of Ab aggregates from 690 nm to 55 nm. At days 2
and 3, the average length of protofibrils in the presence of 5x was
758 and 641 nm, respectively, but short protofibrils of length less
than 100 nm were predominantly observed in the presence of 10x
(Table 1). These findings support the idea that ER promoted the
formation of stable intermediate protofibrils.
Furthermore, ER likely limited the capability to form longer
fibrils. Therefore, next we determined whether the inhibition of
fibril formation was dependent on ER concentration using ThT
fluorescence assay. In the absence of ER, there was a steady
increase in the ThT fluorescence of Ab samples throughout the
study (Figure 3A). In particular, a steep increase in the
fluorescence was observed from 48 to 72 hr, indicating amyloid
fibril formation. However, as the ER concentration varied from
0.01x to 10x, a substantial reduction in the ThT fluorescence was
observed (Figure 3A). However, the ThT data of the Ab
aggregates formed with ER should be interpreted with caution
due to interference of ER with the ThT fluorescence measure-
ment. In order to investigate the interference of ER with the ThT
fluorescence, three different concentrations of ER (1x, 3x, and 10x)
were added to the Ab aggregates incubated without any ER for 3
days displaying a high ThT fluorescence intensity. Addition of 1x,
3x, or 10x ER caused 66%, 81%, and 88% reduction in the Ab
aggregate fluorescence, respectively (Figure 3B), suggesting that
ER competitively binds to ThT bindings sites on Ab fibrils.
However, the ThT fluorescence of the Ab aggregates formed with
1x or 3X ER for 3 days was twice lower than that of the Ab
aggregates at day 3 mixed with 1x or 3x ER respectively,
suggesting that the ER-induced Ab protofibrils weakly bind ThT
compared to Ab fibrils. Glabe et al. also reported that Ab fibrillar
oligomers with stacked b-sheet structure are OC-antibody reactive
but weakly bind ThT [26].
In summary, co-incubation of Ab with ER concentrations of 1x
or greater inhibits high-molecular weight Ab fibril formation and
leads to formation of protofibrils and stabilization of the
protofibrils at least up to 3 days. At day 1, the average length of
Ab protofibrils is inversely proportional to the concentration of ER
at the concentration of 1x ER or greater (Table 1).
Immuno-reactivity changes of Ab aggregates by ER
Dot blotting with Ab-specific antibodies was also used to monitor Ab
aggregate formation. These assays were performed to obtain an
integrated picture of Ab aggregation modulation by ER. With Ab-
specific antibodies, dot blotting has become an effective method for
monitoring Ab aggregate formation [1,26,27,28,29,30]. Four Ab-
specific antibodies were utilized for this purpose. 4G8 is an Ab-
sequence-specific monoclonal antibody [31,32,33,34] that binds to
amino acids 17 to 24 of Ab, the hydrophobic patch of Ab.6 E 1 0i sa
monoclonal antibody that recognizes Ab residues 1-16 [28,35]. A11 is
a polyclonal antibody that reacts with soluble toxic oligomers and
protofibrils [7,28,30]. OC is a polyclonal antibody that reacts with
aggregates with fibrillar structure, including fibrillar oligomers,
protofibrils and fibrils [28,29].
Figure 2. TEM images of Ab aggregates. Ab monomers were incubated for one to three days in the absence (no ER) (far-left panels) and the
presence of 1x (middle-left panels), 5x (middle-right panels), or 10x ER (far-right panels) and visualized by TEM. Scale bars are 100 nm.
doi:10.1371/journal.pone.0025752.g002
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day 0 to 2, whereas 4G8-reactivity was nearly negligible at day 3.
Considering that the 4G8 epitope lies in a hydrophobic patch of the
Ab peptide that is known to be buried during amyloid fibril
formation, a dramatic loss of the 4G8 signal was regarded as the
onset of extensive fibril-mesh networking [35]. The loss of 4G8
signal corresponding to the formation of fibril-mesh networks was
also confirmed by TEM results (Figure 2, far-left panels). In
contrast, in the presence of 1x ER or greater, there was prominent
4G8-reactivity even at day 3 indicating that fibril-mesh networks
were not readily formed, which is consistent with TEM results. In
the absence of ER, significant 6E10 reactivity was observed from
day 0 to 2. Under these conditions, the N-terminus of Ab, the 6E10
epitope,is easilyaccessible to the 6E10 antibody. At day3, only very
weak 6E10 signal was detected, which is most probably due to Ab
conformation change restricting 6E10 antibody binding similar to
4E8. However, as ER concentration was increased from 1x to 10x,
6E10 reactivity decreased significantly even at day 1 and 2. At the
concentration of 10x ER, 6E10 reactivity was significantly weaker
than reactivity in the absence of ER (Figure 4). This suggests that
ER interaction with Ab inhibits 6E10 binding. There are two
possible mechanisms. First ER competitively binds to the 6E10
epitope. Second, ER alters the conformation of Ab limiting
antibody accessibility to the 6E10 epitope, essentially hiding the
N-terminus. According to the structural model of Ab40 fibril
proposed by Grigorieff et. al., two pairs of Ab protofibrils intertwine
adjacently to form a fibril with a 20 nm cross-sectional width [36],
which is consistent with the 20 nm Ab-fibril cross-sectional width
observed in Figure 5 (no ER panel). In their model, the N-terminus
of each protofibril is laterally exposed and interlocked to form a
fibril. Based on this Ab40 fibril structural model, we speculate that
ER binding disrupts the coalescence of two protofibrils leading to
inhibitionofamyloidfibrilformation. This isalsoconsistentwith the
results that ER-induced oligomers/protofibrils (7 nm cross-sectional
width) are stable and do not form fibrils (Figure 5).
In the absence of ER, significant A11-signals were detected at
day 1 and 2 but not at day 3 indicating the A11-reactive species
were formed until day 2 but converted into amyloid fibrils between
day 2 and 3. In contrast, when 1x ER was present, A11-signal was
detected even at day 0 and persisted until day 3. In the presence of
3x, 5x, and 10x ER, substantial A11-signal was detected from day
1 to 3, which is consistent with predominant protofibrils but no
Table 1. Length distribution of Ab aggregates incubated in the presence of 1x, 5x, and 10x for one, two, and three days.
a
ER Conc. Length of Ab aggregates (mm)
b
Average (nm)
0.1 0.2 0.3 0.4 0.5 0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4 .1.4
D a y 1 1 x N D2 01 7 2 7 1 72 21 12 17 1 377941 8 6 9 0 6 430
5x 1 25 68 63 25 15 3 ND ND ND ND ND ND ND ND 320 6 110
1 0 x 1 8 7 1 2 1N D N DN DN DN DN DN DN D N D N D N D N D 5 5 6 27
D a y 2 1 x N D9 2 0 2 5 2 41 61 71 82 11 594521 5 7 0 2 6 424
5 x N DN D19 2 12 82 83 42 82 573583 7 5 8 6 263
1 0 x 1 6 2 3 7 1N D N DN DN DN DN DN DN D N D N D N D N D 7 3 6 37
D a y 3 1 x 1 1 61 3 1 8 1 52 11 62 01 79 99652 5 7 8 4 6 485
5x ND 3 8 23 25 31 31 33 16 18 4 3 5 ND ND 642 6 233
1 0 x 1 5 1 4 5 4N D N DN DN DN DN DN DN D N D N D N D N D 8 3 6 41
a: Two hundred Ab aggregates observed in negative-stain TEM images at each concentration of ER were analyzed.
b: Each bin has an 100 nm interval in the length of Ab aggregates. The number indicates the maximum length of Ab aggregates in each bin.
ND: Not Detected.
doi:10.1371/journal.pone.0025752.t001
Figure 3. ThT fluorescence of Ab samples. Ab monomers were
incubated for four days in the absence (no ER) or in the presence of
0.01x, 0.1x, 0.5x, 1x, 3x, 5x, or 10x of ER (A). Preformed amyloid fibrils (72
hrs) were mixed with varying concentrations of ER (1x, 3x, and 10x ER).
ThT fluorescence was measured in arbitrary units (a.u.). Values represent
means 6 standard deviation (n=3).
doi:10.1371/journal.pone.0025752.g003
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presence of ER, OC-reactive signals remain unchanged (Figure 4)
indicating that ER-induced protofibrils still have fibrillar struc-
tures. These dot-blotting results support the idea that ER induces
formation of both A11- and OC-reactive oligomers but inhibits
fibril formation.
Modulation of aggregation of Ab and a-synuclein by ER
All of these findings strongly support the idea that ER is an
efficient aggregation modulator. ER promotes the formation of Ab
protofibrils and stabilizes them for at least three days, which in turn
inhibits fibril formation. Based on the Ab40 fibril structural model
proposed by Grigorieff et. al. and the immunoassay results using the
Ab N-terminus specific antibody, inhibition of Ab fibril formation is
at least partly due to ER binding to the Ab N-terminus by blocking
bindingoftwoprotofibrilstoformonefibril.Asmentioned earlier,it
is worthwhile to compare modulation of aggregation of a-synuclein
and Ab by ER. Previous studies on a-synuclein aggregation [12]
and our findings indicate that ER promotes protofibril formation of
both a-synuclein and Ab. ER binding sites were found to be
predominantly on the hydrophobic region of non-Ab component of
AD amyloid [12]. Therefore, the authors speculate that ER
facilitates hydrophoboic interaction of a-synuclein leading to fast
protofibril formation. Similarly aromatic rings of ER might play a
key role in the promotion of Ab aggregation at 1x ER
concentration. However, although the concentration of ER
increased up to 10x, the hydrophobic patch of Ab (4G8 epitope)
was not completely buried, suggesting that the interaction mode of
ER with Ab is different from that with a-synuclein. A bigger
difference was found in the effects of xanthene dyes on fibril
formation of a-synuclein and Ab. Although xanthene dyes lead to
formation of a-synuclein fibrils, ER clearly inhibits formation of Ab
fibrils. These comparisons suggest that ER promotes protofibril
formation of both a-synuclein and Ab most probably due to the
interaction of xanthene aromatic rings with the hydrophobic region
of each protein. However, ER is thought to bind to the N-terminus
of Ab leading to the inhibition of Ab fibril formation, which
distinguishestheERinteraction with Ab fromthat witha-synuclein.
Inhibition of Ab-induced impaired cellular reducing
activity by ER
Modulation of Ab aggregation by ER was clearly demonstrated
in the previous sections. However, since Ab oligomers and
protofibrils are normally considered toxic species, we wanted to
determine whether ER-induced Ab protofibrils perturb cellular
activities of neuronal cells. In order to determine the detrimental
effects of ER-induced Ab aggregates on cellular functions, we
chose the cellular MTT reducing activity of SH-SY5Y neuroblas-
toma cells. MTT reducing activity has been widely considered as
an indication of cell viability [8,29,37,38]. Therefore, the MTT
reducing activity loss has often been interpreted as the Ab-
associated cytotoxicity [7,28,39,40,41,42,43]. However, due to a
potential issue of the promoted export of the reduced MTT from
the cells upon Ab aggregate treatment leading to reduction of the
MTT signal [44,45,46], we avoided direct interpretation of the
reduced MTT signal as Ab-associated cytotoxicity but considered
the reduced MTT signal as an indication of impaired cellular
functions. Cells were adminstered Ab aggregates preformed in the
absence or presence of ER. Preformed Ab aggregates were
prepared by incubating 50 mMA b monomers in the absence or
presence of various concentrations of ER (1x to 10x) at 37uC for
Figure 4. Dot-blotting of Ab samples using four Ab-specific antibodies. Ab monomers were incubated at 37uC in the absence (no ER) or
presence of the indicated concentrations of ER (from 1x to 10x) for up to 3 days. Samples were spotted onto a nitrocellulose membrane and
immunostained with the 4G8, 6E10, A11, or OC antibody.
doi:10.1371/journal.pone.0025752.g004
Figure 5. TEM images of Ab aggregates after three day
incubation. Ab monomers were incubated for three days in the
absence (no ER) or in the presence of 1x, 5x, or 10x ER and visualized by
TEM. Scale bars are 20 nm.
doi:10.1371/journal.pone.0025752.g005
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5 mM preformed aggregates for 48 hours, and subsequently MTT
reducing activity was determined.
As a control, the MTT reducing activity of cells treated with
varying concentrations of ER was measured. Up to 10x ER
(500 mM), there was only slight reduction (5%) in the MTT
reduction. At day 0, Ab monomers (5 mM) caused 10% reduction
(P,0.001) in the MTT reduction probably due to the toxic Ab
aggregate formation during the Ab monomer incubation with the
cells for 48 hr (Figure 6). However, in the presence of 10x ER, the
MTT reducing activity was recovered to 95%. At day 1, preformed
Ab species formed in the absence of ER significantly reduced the
MTT reducing activity by 28%. This loss of the MTT reducing
activity likely resulted from the formation of both A11- and OC-
reactive protofibrils (Figure 4). However, preformed Ab species
prepared in the presence of 10x ER showed an MTT reducing
activity significantly higher than those of the Ab incubated without
any ER at days 0 and 1 (P,0.001 and ,0.005, respectively) up to
the level of a negative control without any Ab (Figure 6). At day 1,
ER reduced the Ab-induced loss of the MTT reducing activity in a
dose-dependent manner (Figure 7). At 1x ER, there was only 8%
recovery of the MTT reducing activity (P,0.001). However, the
MTT reduction reaches close to 100% in the presence of 10x ER.
Similar results were shown with preformed Ab on subsequent days.
The cellulr MTT reducing activity with Ab (5 mM) incubated for 2
and 3 days decreased to 69% and 66%, respectively. In particular,
co-incubation of 10x ER raised the MTT reducing activity to 96
and 98% at day 2 and 3, respectively (Figure 6).
Based on the cellular MTT reduction results, we comprehen-
sively conclude that 10x ER substantially mitigates Ab-induced
impaired MTT reducing activity of neuronal cells. Moreover,
these findings strongly support the idea that the majority of
protofibrils formed in the presence of 10x ER observed in TEM in
fact are not detrimental to neuronal cells, though the protofibrils
are both A11- and OC-reactive. These results also suggest that ER
mitigates Ab-associated damage to the cellular function by
blocking specific sequence of low molecular weight Ab species
that confers damages to neuronal cells. However, even at 10x ER
the protofibrils formed are A11- and OC-reactive, suggesting that
ER binding sites on the Ab do not overlap with the epitope of
either A11 or OC antibody.
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